reports
Standard BioTools Enters Next Phase of Transformation with Strategic S...
Standard BioTools Enters Next Phase of Transformation with Strategic Sale of SomaLogic to Illumina Up To $425 Million In Total Proceeds Inclusive of Near-term Milestone Payments; $350 Million In Upfront Cash Retains Strategic Upside with Illumina Protein Prep Royalty Stream and Rights to Single SOMAmer Reagent Business Simplifies Operating Structure and Enables Achievement of Adjusted EBITDA Break-Even Cash & Cash Equivalents of At Least $550 Million Expected at Close to Fuel Inorganic Growth Strategy and Drive Long-Term Value Creation SOUTH SAN FRANCISCO, Calif., June 23, 2025 (...
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Se...
Standard BioTools to Host Inaugural “Proteomics Roundtable” Webcast Series Featuring top researchers and industry experts using high-throughput proteomics to drive breakthroughs in population health, translational research and clinical development SOUTH SAN FRANCISCO, Calif., May 30, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of its inaugural – a program of virtual events designed to spark conversation about the rapidly evolving field of proteomics. The series will spotlight thought leaders and industry experts discussing groundbreaking res...
Standard BioTools Reports First Quarter 2025 Financial Results
Standard BioTools Reports First Quarter 2025 Financial Results SOUTH SAN FRANCISCO, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the first quarter ended March 31, 2025. Recent Highlights: First quarter 2025 revenue of $40.8 million45% reduction in operating loss and 29% improvement in adjusted EBITDA year-over-yearOperationalized $10 million more in annual run rate cost reductions, totaling $90 million since merger Strong balance sheet with $261 million in cash & cash equiva...
Standard BioTools Announces New Product Innovations in Plasma and Sing...
Standard BioTools Announces New Product Innovations in Plasma and Single-Cell Proteomics at AACR 2025 Expanded suite of consumables, instruments and services designed to empower researchers and accelerate next-generation drug development Ninety posters and presentations at AACR powered by the Standard BioTools proteomic portfolio to advance cancer research from target discovery to clinical development SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced the launch of new and enhanced proteomic product offerings at the upcom...
Standard BioTools Schedules First Quarter Earnings Conference Call on ...
Standard BioTools Schedules First Quarter Earnings Conference Call on May 6, 2025 SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report first quarter 2025 financial results on Tuesday, May 6, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US callers: (412) 902-4297 Live audio of the webca...
- Jonathan Moreland
VAC MARRIOTT VACATIONS WORLDWIDE CORPORATION
TDOC TELADOC HEALTH INC.
PBF PBF ENERGY INC. CLASS A
OMI OWENS & MINOR INC.
MTDR MATADOR RESOURCES COMPANY
LTRX LANTRONIX INC.
JCOM J2 GLOBAL INC.
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FLDM FLUIDIGM
CDXS CODEXIS
FMC FMC CORPORATION
GTN GRAY TELEVISION INC.
PETS PETMED EXPRESS INC.
DMLP DORCHESTER MINERALS L.P.
LBSRD LIBERTY STAR URANIUM & METALS
GO GROCERY OUTLET HOLDING
PSN PARSONS
CAPR CAPRICOR THERAPEUTICS
VERX VERTEX
ORIC INC.
NOG ORIC PHARMACEUTICALS
PFBX NORTHERN OIL AND GAS
ALIT PEOPLES FINANCIAL CORP. (MISSISSIPPI)
TMCI ALIGHT
AVDX INC. / DELAWARE
FLYW TREACE MED CONCEPTS INC
MBC_w AVIDXCHANGE HLDGS INC
MRNA FLYWIRE CORP
CVI MASTERBRAND INC
GF MODERNA
INC.
CVR ENERGY
INC.
THE NEW GERMANY FUND
INC.
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that company management will participate in the following investor conferences: TD Cowen’s 45th Annual Healthcare Conference - March 3rd – 5th, 2025 Presenting on Monday, March 3, 2025, at 3:10 p.m. ET2025 Leerink Partners Global Healthcare Conference - March 9th – 12th, 2025Participating in investor meetings on March 12thKeyBanc’s 5th Annual Healthcare Forum – March 18th & 19th, 2025Presenting on Wednesday, ...
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial ...
Standard BioTools Reports Fourth Quarter and Full Year 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company” or “Standard BioTools”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2024. Recent Highlights: Full Year 2024 pro forma combined revenue of $175.1 million17% Full Year reduction in pro forma operating loss and 33% year over year improvement in adjusted EBITDA Additional $10 million in operational cost reductions, now totaling $90 million in synergies o...
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings...
Standard BioTools Schedules Fourth Quarter and Full Year 2024 Earnings Conference Call on February 26, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 12, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report fourth quarter and full year 2024 financial results on Wednesday, February 26, 2025, after market close. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss its financial results and operational progress. Individuals can access the conference call by dialing: US domestic callers: (888) 346-3970Outside US ...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2...
Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2024 Revenue Preliminary, unaudited revenue for the full year 2024 of approximately $174 million Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16th, 2024, at 9:45 a.m. PT. SOUTH SAN FRANCISCO, Calif., Jan. 13, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (“Standard BioTools” or the “Company”) today announced preliminary and unaudited revenue results for the fourth quarter and full year 2024. Standard BioTools expects fourth quarter 2024 revenue of approxi...
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide ...
Standard BioTools SomaScan Assay Powers Key Insights into Semaglutide Treatment Published in Nature Medicine Novo Nordisk initiated study validates the power of proteomics to provide unique insights into mechanisms of action and expanded drug indications as well as the potential for shorter and smaller clinical trials SOUTH SAN FRANCISCO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) announced today that its SomaScan™ Platform played a pivotal role in a study published in the current issue of titled “Proteomic changes upon treatment with...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare...
Standard BioTools to Present at the 43rd Annual J.P. Morgan Healthcare Conference SOUTH SAN FRANCISCO, Calif., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference taking place on January 13th - 16th at the Westin St. Francis Hotel in San Francisco, CA. Dr. Egholm’s corporate presentation will be held on January 16th, 2024, at 9:45 a.m. PT. A live audio webcast will be available to investors and other interested ...
Standard BioTools Appoints Alex Kim as Chief Financial Officer
Standard BioTools Appoints Alex Kim as Chief Financial Officer SOUTH SAN FRANCISCO, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (“Standard BioTools” or the “Company”) (Nasdaq: LAB) today announced the appointment of Alex Kim as Chief Financial Officer, effective November 11, 2024. Kim, a co-founder and most recently Chief Operating Officer of Standard BioTools, brings nearly 30 years of financial and operations experience in the healthcare and life sciences industries to the role and will oversee Standard BioTools’ finance organization. Michael Egholm, President and ...
Standard BioTools to Participate in Upcoming Investor Conferences
Standard BioTools to Participate in Upcoming Investor Conferences SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that its management team will participate in the following investor conferences in the month of November: UBS Global Healthcare Conference on November 12th, 2024President and CEO, Michael Egholm, PhD, will participate in a corporate presentation on Tuesday, November 12, 2024, at 1:15 p.m. PTJefferies London Healthcare Conference on November 19th – 21st, 2024President and CEO, Michael Egholm, PhD, will par...
Standard BioTools Reports Third Quarter 2024 Financial Results
Standard BioTools Reports Third Quarter 2024 Financial Results SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) (the “Company”) today announced unaudited interim financial results for the third quarter ended September 30, 2024. Recent Highlights: Reported third quarter 2024 revenue of $45 million Ongoing merger cost synergy realization delivered 50% adjusted EBITDA improvement and 35% net loss improvement year-over-yearOperationalized approximately $80 million in merger synergies, expected to be fully realized in 2025, and r...
Standard BioTools Announces Conference Call and Webcast for Third Quar...
Standard BioTools Announces Conference Call and Webcast for Third Quarter 2024 Financial Results on October 30, 2024 SOUTH SAN FRANCISCO, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (NASDAQ: LAB) today announced that it will report third quarter 2024 financial results on Wednesday, October 30, 2024, after the close of the market. The Company’s management will host a conference call and webcast at 1:30 p.m. PT, 4:30 p.m. ET, on October 30, 2024, to discuss third quarter 2024 financial results and operational progress. A press release including the financial results wi...
Standard BioTools Achieves New Record of the Most Protein Measurements...
Standard BioTools Achieves New Record of the Most Protein Measurements on the Most Sample Types with Expansion of the SomaScan® 11K Platform Cerebrospinal fluid, cell lysates and tissue homogenates open new avenues for biomarker discovery in oncology and neurology SOUTH SAN FRANCISCO, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), today announced that the SomaScan® 11K Platform now includes protein measurements on a broader range of sample types, including cerebrospinal fluid (CSF), aqueous humor, tissue homogenates and cell lysates. The SomaScan® Platfo...
Standard BioTools proteomics profiling reveals unique biomarkers and i...
Standard BioTools proteomics profiling reveals unique biomarkers and insights into nonalcoholic steatohepatitis (NASH) Researchers used Standard BioTools’ high-content SomaScan® Platform and SomaSignal™ tests for MASH/NASH to identify 69 blood biomarkers that correlate with clinical measures of liver disease SOUTH SAN FRANCISCO, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB) today announced a , by researchers at Pfizer Research and Development, that detailed their use of the high-plex SomaScan® Assay, leveraging an industry-leading 7,000-protein biomarker...
- Jonathan Moreland
TTSH TILE SHOP HOLDINGS INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
PBF PBF ENERGY INC. CLASS A
OOMA OOMA
MPAA MOTORCAR PARTS OF AMERICA INC.
LANC LANCASTER COLONY CORPORATION
IMMR IMMERSION CORP.
HNRG HALLADOR ENERGY CO.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
FFIN FIRST FINANCIAL BANKSHARES INC
CTRN CITI TRENDS INC.
CRK COMSTOCK RESOURCES INC.
BEN FRANKLIN RESOURCES INC.
APEI AMERICAN PUBLIC EDUCATION
ATEC ALPHATEC HOLDINGS INC.
DKL DELEK LOGISTICS PARTNERS
MYRG MYR GROUP INC.
EPD ENTERPRISE PRODUCTS PARTNERS L.P.
GBDC GOLUB CAPITAL BDC INC.
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ISDR ISSUER DIRECT CORP.
AXR AMREP
ELAN ELANCO ANIMAL HEALTH INC.
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
GRWG GROWGENERATION
ONEW ONEWATER MARINE
BILL BILL.COM HOLDINGS
HPK HIGHPEAK ENERGY INC (A)
ABCL ABCELLERA BIOLOGICS
LESL LESLIES
BFLY BUTTERFLY NETWORK INC (A)
INBX INHIBRX
IMMX INC.
NN IMMIX BIOPHARMA INC
NXGL NEXTNAV INC
BIGZ NEXGEL INC
PFHC BLACKROCK INNOVATION AND GROWTH TST
CALC PROFRAC HLDG CORP
ATMU CALCIMEDICA INC.
ET ATMUS FILTRATION TECHNOLOGIES INC
MIO ENERGY TRANSFER LP
PEO PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
SUNS PETROLEUM & RESOURCES CORPORATION
XPER SUNRISE REALTY TRUST
OBDE XPERI INC
LOCO OWL ROCK CAPITAL CORP III
LOVE OIL INC.
- Jonathan Moreland
MPAA MOTORCAR PARTS OF AMERICA INC.
LANC LANCASTER COLONY CORPORATION
IMMR IMMERSION CORP.
GLP GLOBAL PARTNERS LP
FLDM FLUIDIGM
CTRN CITI TRENDS INC.
APEI AMERICAN PUBLIC EDUCATION
GBDC GOLUB CAPITAL BDC INC.
BRN BARNWELL INDUSTRIES
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
APPN APPIAN
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
ISDR ISSUER DIRECT CORP.
AXR AMREP
UPWK UPWORK
HPK HIGHPEAK ENERGY INC (A)
ABCL ABCELLERA BIOLOGICS
NVTS NAVITAS SEMICONDUCTOR CORP
PFHC PROFRAC HLDG CORP
SRBK SR BANCORP INC
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.